Wikidata

(Q113921734)

English

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

clinical trial

In more languages

Statements

short name
SERENA-6 (English)
0 references
title
A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study (English)
0 references
country
Australia
0 references
Austria
0 references
Bulgaria
0 references
Canada
0 references
France
0 references
Germany
0 references
Hungary
0 references
Italy
0 references
Japan
0 references
Poland
0 references
Portugal
0 references
Spain
0 references
Switzerland
0 references
Taiwan
0 references
Turkey
0 references
United Kingdom
0 references
start time
30 June 2021
0 references
end time
28 September 2023
0 references
number of participants
302
0 references
minimum age
18 year
0 references
maximum age
130 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q113921734&oldid=2148783599"